Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain

Melbourne (Australia) and Madrid (Spain) – 8 December 2021. Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in Spain. 

Telix is pleased to announce that it has entered into an exclusive commercial distribution agreement with Madrid-based NUCLIBER S.A. (NUCLIBER) for Telix’s prostate cancer investigational imaging product, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) for the Spanish market. 

Under the terms of the agreement, and subject to closing requirements being satisfied, NUCLIBER will be the overall distributor and local representative for Illuccix in Spain, an EU5 country, from the national approval date. NUCLIBER has demonstrated experience in the supply of gallium generators across Spain and has been selected according to its ability to deliver a secure and continuous supply of 68Ga necessary for commercial launch in the country.  

NUCLIBER Managing Director, Marisol Fornes stated, “We are delighted to be working with Telix and adding the Company’s lead investigational asset to our future nuclear medicine offering in Spain. With recent updates to European and U.S. clinical practice guidelines, PSMA-PET is emerging as the standard of care for prostate cancer imaging worldwide. Through this commercial partnership we will support Telix in pursuit of its goal to provide widespread access to state-of-the-art diagnostic imaging for Spanish men living with prostate cancer following marketing authorisation in Spain.”   

Telix EMEA President Richard Valeix added, “NUCLIBER is a leading nuclear medicine company in Spain, and we are therefore pleased to have entered into this commercial distribution agreement as we prepare for the European launch of Illuccix. Collaborating with such an established and patient-centric leader in radiopharmaceuticals will help Telix to deliver on the promise of nuclear medicine with the ultimate aim to improve outcomes for Spanish men living with prostate cancer.”   

To read the full ASX disclosure please click here. 

To return to Telix’s homepage please click here.